- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03328195
Vielight Neuro RX Gamma - Feasibility Pilot
A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Vielight Neuro RX Gamma Device for the Treatment of Moderate-to-severe Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Neuro RX Gamma system is a headset which emits pulsed near-infrared energy synchronously or asynchronously through diodes placed on the scalp and inside a nostril.
A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment synchronized, treatment asynchronized or sham (placebo). A dedicated caregiver will apply the device to the subject for 20 minute daily sessions at home, 6 days a week for a total of 12 weeks. The subject and caregiver will be required to return to the clinic for follow-up assessments after 3, 6 and 12 weeks of treatment. Participants will have the choice of opting into a substudy involving the collection of rest EEG recordings during the baseline and weeks 3, 6 and 12 visits.
60 patients will be enrolled in 2 clinical sites in Ontario, Canada.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M3B2S7
- Toronto Memory Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age is greater than or equal to 50 years old
- Meets the criteria for probable Alzheimer's disease of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
- If receiving ongoing cholinesterase inhibitor therapy and/or memantine, must be on a stable dosage for at least the prior 3 months
- Mini Mental State Examination (MMSE) score between 0-20 at screening assessment
- Severe Impairment Battery score at baseline of ≤90
- Outpatient with a reliable caregiver willing to commit to study visits and procedures
Exclusion Criteria:
- Current psychiatric or other neurologic disease
- Any history of stroke, seizures, light sensitivity (polymorphous light eruption, solar urticaria, persistent light reactivity) or Lyme disease, including those taking photosensitizing medication
- Currently undergoing light therapy treatment
- Increased skin sensitivity at the treatment site including active herpes simplex in the treatment area, history of keloid formation, or history of retinoid use in the past month
- Pregnant or lactating or planning to become pregnant
- Any issues with ambulation, vision, or hearing which could, in the opinion of the investigator, interfere with their ability to complete assessments
- Does not speak English at a level necessary for the completion of the assessments.
- Currently participating in another clinical research study involving an investigational product.
- Has participated in a drug or device study within the last 30 days.
- Any condition, such as agitation/aggression, that in the opinion of the investigator would cause the patient to be unable to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Neuro RX Gamma synchronous
Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
|
Twenty minute treatment, six days per week for 12 weeks
|
Sham Comparator: Sham light therapy
Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
|
Twenty minutes, six days per week for 12 weeks with sham device
|
Active Comparator: Neuro RX Gamma asynchronous
Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.
The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
|
Twenty minutes, six days per week for 12 weeks with sham device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Severe Impairment Battery (SIB) score - An assessment of Severe Dementia in the elderly.
Time Frame: Baseline to Week 12
|
The SIB evaluates cognitive abilities in severely impaired individuals.
This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name.
There are 40 items and the SIB score ranges from 0-100.
Individuals who score less than 63 on the SIB are rated as very severely impaired.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device safety according to the number of device-related adverse events
Time Frame: Baseline to Week 12
|
Subjects will be monitored for clinical evidence of device-related adverse events throughout the study.
|
Baseline to Week 12
|
Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly.
Time Frame: Baseline to Week 3
|
The SIB evaluates cognitive abilities in severely impaired individuals.
This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name.
There are 40 items and the SIB score ranges from 0-100.
Individuals who score less than 63 on the SIB are rated as very severely impaired.
|
Baseline to Week 3
|
Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly.
Time Frame: Baseline to Week 6
|
The SIB evaluates cognitive abilities in severely impaired individuals.
This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name.
There are 40 items and the SIB score ranges from 0-100.
Individuals who score less than 63 on the SIB are rated as very severely impaired.
|
Baseline to Week 6
|
Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score
Time Frame: Baseline to Week 3
|
The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease.
The assessment includes 19 questions.
The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score.
The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.
|
Baseline to Week 3
|
Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score
Time Frame: Baseline to Week 6
|
The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease.
The assessment includes 19 questions.
The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score.
The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.
|
Baseline to Week 6
|
Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score
Time Frame: Baseline to Week 12
|
The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease.
The assessment includes 19 questions.
The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score.
The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.
|
Baseline to Week 12
|
Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview.
Time Frame: Baseline to Week 3
|
The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).
|
Baseline to Week 3
|
Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview.
Time Frame: Baseline to Week 6
|
The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).
|
Baseline to Week 6
|
Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview.
Time Frame: Baseline to Week 12
|
The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).
|
Baseline to Week 12
|
Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score.
Time Frame: Baseline to Week 3
|
The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment.
It is intended to be used as a measure of clinically meaningful change.
The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial.
It relies on both direct examination of the patient and interview of the caregiver.
Scored as marked/moderate/minimal improvement or worsening or no change.
|
Baseline to Week 3
|
Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score.
Time Frame: Baseline to Week 6
|
The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment.
It is intended to be used as a measure of clinically meaningful change.
The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial.
It relies on both direct examination of the patient and interview of the caregiver.
Scored as marked/moderate/minimal improvement or worsening or no change.
|
Baseline to Week 6
|
Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score.
Time Frame: Baseline to Week 12
|
The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment.
It is intended to be used as a measure of clinically meaningful change.
The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial.
It relies on both direct examination of the patient and interview of the caregiver.
Scored as marked/moderate/minimal improvement or worsening or no change.
|
Baseline to Week 12
|
Change in the Electroencephalogram's (EEG) overall power spectral density
Time Frame: Baseline to Week 12
|
The EEG recordings will give insight into the effect on the neural activity of the brain of the Neuro RX Gamma synchronized and Neuro RX Gamma asynchronized compared to sham.
|
Baseline to Week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Caregiver reported treatment compliance
Time Frame: 12 weeks
|
Caregivers will document treatment sessions in a logbook to monitor compliance.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P17.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Neuro RX Gamma synchronous
-
Unity Health TorontoRecruitingMCI | Amnestic Mild Cognitive DisorderCanada
-
Vielight Inc.Not yet recruitingPost COVID-19 Cognitive ImpairmentUnited States
-
University of California, San FranciscoCompletedAlzheimer DiseaseUnited States
-
University of California, San FranciscoCompletedDementia, Alzheimer TypeUnited States
-
Multicenter Clinical Study Group of Osaka, Colorectal...WithdrawnPostoperative Complications | PeritonitisJapan
-
Assistance Publique - Hôpitaux de ParisTerminatedANCA + Vasculitides Relapsing Either Under Corticosteroid | and Immunosuppressant Therapies or After One Year | Post Treatment.France
-
Hoffmann-La RocheCompletedKidney Failure, ChronicUnited States